<p>GLOBALT Investments LLC GA 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在安进（Amgen Inc.，NASDAQ:AMGN - 免费报告）的持股比例提高了 25.4%。该机构投资者在本季度额外购买了 5,247 股后，持有该医疗研究公司 25,923 股股票。GLOBALT Investments LLC GA 在安进的持股在最近的报告期末价值为 8,485,000 美元。</p>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对其在 AMGN 的持仓进行了调整。Anfield Capital Management LLC 在第四季度将其在安进的持股提高了 1,000.0%。Anfield Capital Management LLC 目前持有 77 股该医疗研究公司的股票，价值 25,000 美元，此前在上个季度又购买了 70 股。Dogwood Wealth Management LLC 在第四季度将其在安进的持仓增加了 275.0%。Dogwood Wealth Management LLC 目前持有 75 股该医疗研究公司的股票，价值 25,000 美元，此前在上个季度又购买了 55 股。养老金保护基金董事会在第四季度购买了安进的新股份，估计价值约为 26,000 美元。Manning &amp; Napier Advisors LLC 在第四季度将其在安进的持股提高了 49.2%。Manning &amp; Napier Advisors LLC 目前持有 97 股该医疗研究公司的股票，价值 32,000 美元，此前在上个季度又购买了 32 股。最后，Olistico Wealth LLC 在第四季度购买了安进的新股份，价值约为 33,000 美元。对冲基金和其他机构投资者持有该公司 76.50% 的股票。</p>
<h2>安进价格表现</h2>
<p>安进（AMGN）周一开盘价为 326.31 美元。该公司的市值为 1,761 亿美元，市盈率为 22.71，市盈增长比率为 3.28，贝塔值为 0.44。该公司的 50 天移动平均线为 349.17 美元，200 天移动平均线为 343.36 美元。安进的债务与股本比率为 5.65，速动比率为 1.01，流动比率为 1.26。安进的 52 周低点为 267.73 美元，52 周高点为 391.29 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）上一次发布季度财报是在 4 月 30 日（星期四）。该医疗研究公司报告本季度每股收益为 5.15 美元，超出市场共识预期的 4.77 美元，超出幅度为 0.38 美元。该公司本季度的收入为 86.2 亿美元，而分析师预期为 85.8 亿美元。安进的净利润率为 20.96%，股本回报率为 137.41%。该公司本季度的收入同比增长 5.8%。在去年同期，该公司每股收益为 4.90 美元。安进已将其 2026 财年的指导目标设定为每股收益 21.700-23.100 美元。研究分析师平均预计安进在当前年度将发布每股收益 22.37 美元。</p>
<h2>安进股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 6 月 5 日（星期五）支付。5 月 15 日（星期五）的登记投资者将获得每股 2.52 美元的股息。除息日为 5 月 15 日（星期五）。这代表着每年 10.08 美元的股息和 3.1% 的收益率。安进的股息支付比率目前为 70.15%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>几位股票分析师最近对该公司发布了报告。Argus 将安进的目标价格从 360.00 美元上调至 400.00 美元，并在 2 月 6 日（星期五）的报告中给予该公司 “买入” 评级。德意志银行将安进的目标价格从 285.00 美元上调至 295.00 美元，并在 2 月 5 日（星期四）的研究报告中给予该公司 “持有” 评级。Truist Financial 将安进的目标价格从 325.00 美元上调至 327.00 美元，并在 5 月 1 日（星期五）的研究报告中给予该公司 “持有” 评级。瑞银集团将安进的目标价格从 390.00 美元上调至 400.00 美元，并在 4 月 13 日（星期一）的研究报告中给予该公司 “买入” 评级。最后，Piper Sandler 将安进的目标价格从 432.00 美元下调至 427.00 美元，并在周四的研究报告中对该公司设定了 “增持” 评级。两位分析师对该股票给予了强烈买入评级，十三位给予了买入评级，十四位给予了持有评级，二位给予了卖出评级。根据 MarketBeat.com 的数据，安进的共识评级为 “持有”，共识目标价格为 356.15 美元。</p>
<p><strong>查看我们最新的安进股票报告</strong></p>
<h2>内部人士下注</h2>
<p>在相关消息中，SVP Nancy A. Grygiel 于 5 月 4 日（星期一）出售了 1,237 股该股票。股份以平均价格 323.73 美元出售，总交易额为 400,454.01 美元。交易完成后，该高级副总裁在公司持有 7,009 股，价值约为 2,269,023.57 美元。这代表着其持股减少了 15.00%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。内部人士持有该公司 0.85% 的股票。</p>
<h2>关于安进</h2>
<p>（免费报告）</p>
<p>安进（Amgen Inc.，NASDAQ: AMGN）是一家成立于 1980 年、总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过安进</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 关注火热的分拆和并购领域</li>
<li>随着 AI 内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而安进并不在名单上。</p>
<p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

标普全球医疗股指数 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

<p>GLOBALT Investments LLC 在第四季度将其在安进（Amgen Inc.）的持股增加了 25.4%，目前持有 25,923 股，价值 849 万美元。其他机构投资者也调整了他们在安进的持仓。该公司报告了上个季度每股收益（EPS）为 5.15 美元，超出预期，并宣布每股季度分红为 2.52 美元。分析师对安进的目标价格各不相同，评级从强烈买入到卖出不等</p>

<p>GLOBALT Investments LLC GA lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 25.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,923 shares of the medical research company's stock after acquiring an additional 5,247 shares during the quarter. GLOBALT Investments LLC GA's holdings in Amgen were worth $8,485,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>GLOBALT Investments LLC GA 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在安进（Amgen Inc.，NASDAQ:AMGN - 免费报告）的持股比例提高了 25.4%。该机构投资者在本季度额外购买了 5,247 股后，持有该医疗研究公司 25,923 股股票。GLOBALT Investments LLC GA 在安进的持股在最近的报告期末价值为 8,485,000 美元。</p>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its position in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen in the 4th quarter valued at about $26,000. Manning &amp; Napier Advisors LLC lifted its position in shares of Amgen by 49.2% during the 4th quarter. Manning &amp; Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对其在 AMGN 的持仓进行了调整。Anfield Capital Management LLC 在第四季度将其在安进的持股提高了 1,000.0%。Anfield Capital Management LLC 目前持有 77 股该医疗研究公司的股票，价值 25,000 美元，此前在上个季度又购买了 70 股。Dogwood Wealth Management LLC 在第四季度将其在安进的持仓增加了 275.0%。Dogwood Wealth Management LLC 目前持有 75 股该医疗研究公司的股票，价值 25,000 美元，此前在上个季度又购买了 55 股。养老金保护基金董事会在第四季度购买了安进的新股份，估计价值约为 26,000 美元。Manning &amp; Napier Advisors LLC 在第四季度将其在安进的持股提高了 49.2%。Manning &amp; Napier Advisors LLC 目前持有 97 股该医疗研究公司的股票，价值 32,000 美元，此前在上个季度又购买了 32 股。最后，Olistico Wealth LLC 在第四季度购买了安进的新股份，价值约为 33,000 美元。对冲基金和其他机构投资者持有该公司 76.50% 的股票。</p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安进价格表现</h2>
</div><p>AMGN opened at $326.31 on Monday. The firm has a market cap of $176.10 billion, a P/E ratio of 22.71, a PEG ratio of 3.28 and a beta of 0.44. The firm has a 50-day moving average of $349.17 and a 200 day moving average of $343.36. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $267.73 and a fifty-two week high of $391.29.</p>
<div class="lb-trans"><p>安进（AMGN）周一开盘价为 326.31 美元。该公司的市值为 1,761 亿美元，市盈率为 22.71，市盈增长比率为 3.28，贝塔值为 0.44。该公司的 50 天移动平均线为 349.17 美元，200 天移动平均线为 343.36 美元。安进的债务与股本比率为 5.65，速动比率为 1.01，流动比率为 1.26。安进的 52 周低点为 267.73 美元，52 周高点为 391.29 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.37 EPS for the current year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）上一次发布季度财报是在 4 月 30 日（星期四）。该医疗研究公司报告本季度每股收益为 5.15 美元，超出市场共识预期的 4.77 美元，超出幅度为 0.38 美元。该公司本季度的收入为 86.2 亿美元，而分析师预期为 85.8 亿美元。安进的净利润率为 20.96%，股本回报率为 137.41%。该公司本季度的收入同比增长 5.8%。在去年同期，该公司每股收益为 4.90 美元。安进已将其 2026 财年的指导目标设定为每股收益 21.700-23.100 美元。研究分析师平均预计安进在当前年度将发布每股收益 22.37 美元。</p>
</div><h2>Amgen Dividend Announcement</h2>
<div class="lb-trans"><h2>安进股息公告</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen's dividend payout ratio is presently 70.15%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 6 月 5 日（星期五）支付。5 月 15 日（星期五）的登记投资者将获得每股 2.52 美元的股息。除息日为 5 月 15 日（星期五）。这代表着每年 10.08 美元的股息和 3.1% 的收益率。安进的股息支付比率目前为 70.15%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Several equities analysts have recently issued reports on the company. Argus upped their target price on Amgen from $360.00 to $400.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 6th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, February 5th. Truist Financial increased their price target on Amgen from $325.00 to $327.00 and gave the company a &#34;hold&#34; rating in a research report on Friday, May 1st. UBS Group increased their price target on Amgen from $390.00 to $400.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 13th. Finally, Piper Sandler decreased their price target on Amgen from $432.00 to $427.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of &#34;Hold&#34; and a consensus price target of $356.15.</p>
<div class="lb-trans"><p>几位股票分析师最近对该公司发布了报告。Argus 将安进的目标价格从 360.00 美元上调至 400.00 美元，并在 2 月 6 日（星期五）的报告中给予该公司 “买入” 评级。德意志银行将安进的目标价格从 285.00 美元上调至 295.00 美元，并在 2 月 5 日（星期四）的研究报告中给予该公司 “持有” 评级。Truist Financial 将安进的目标价格从 325.00 美元上调至 327.00 美元，并在 5 月 1 日（星期五）的研究报告中给予该公司 “持有” 评级。瑞银集团将安进的目标价格从 390.00 美元上调至 400.00 美元，并在 4 月 13 日（星期一）的研究报告中给予该公司 “买入” 评级。最后，Piper Sandler 将安进的目标价格从 432.00 美元下调至 427.00 美元，并在周四的研究报告中对该公司设定了 “增持” 评级。两位分析师对该股票给予了强烈买入评级，十三位给予了买入评级，十四位给予了持有评级，二位给予了卖出评级。根据 MarketBeat.com 的数据，安进的共识评级为 “持有”，共识目标价格为 356.15 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的安进股票报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders own 0.85% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，SVP Nancy A. Grygiel 于 5 月 4 日（星期一）出售了 1,237 股该股票。股份以平均价格 323.73 美元出售，总交易额为 400,454.01 美元。交易完成后，该高级副总裁在公司持有 7,009 股，价值约为 2,269,023.57 美元。这代表着其持股减少了 15.00%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。内部人士持有该公司 0.85% 的股票。</p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>关于安进</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进（Amgen Inc.，NASDAQ: AMGN）是一家成立于 1980 年、总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li>
<li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li>
<li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li>
<li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过安进</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 关注火热的分拆和并购领域</li>
<li>随着 AI 内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而安进并不在名单上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN

Market Beat

医疗业 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医疗业 ETF - Vanguard

美国制药 ETF - iShares

医药突破 ETF - ALPS

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

德意志银行

Truist Financial

瑞银集团

Piper Sandler Cos

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GLOBALT Investments LLC GA 持有安进公司价值 849 万美元的股票